...
首页> 外文期刊>Bioorganic and Medicinal Chemistry Letters >(2-Aryl-5-methylimidazol-4-ylcarbonyl)guanidines and (2-aryl-5-methyloxazol-4-ylcarbonyl)guanidines as NHE-1 inhibitors.
【24h】

(2-Aryl-5-methylimidazol-4-ylcarbonyl)guanidines and (2-aryl-5-methyloxazol-4-ylcarbonyl)guanidines as NHE-1 inhibitors.

机译:(2-芳基-5-甲基咪唑-4-基羰基)胍和(2-芳基-5-甲基恶唑-4-基羰基)胍作为NHE-1抑制剂。

获取原文
获取原文并翻译 | 示例
           

摘要

A series of (2-aryl-5-methylimidazol-4-ylcarbonyl)guanidines and (2-aryl-5-methyloxazol-4-ylcarbonyl)guanidines were synthesized and evaluated as NHE-1 inhibitors. The structure-activity relationships well matched those of furan derivatives, which were previously investigated. The (2,5-disubstituted)phenyl compounds showed better activities than the other analogues in both imidazole and oxazole compounds. Especially, 2-(2,5-dichlorophenyl)imidazole 52, and 2-(2-methoxy-5-chlorophenyl)imidazole 54 compounds exhibited potent cardioprotective efficacy both in vitro and in vivo as well as high NHE-1 inhibitory activities.
机译:合成了一系列(2-芳基-5-甲基咪唑-4-基羰基)胍和(2-芳基-5-甲基恶唑-4-基羰基)胍,并将其评估为NHE-1抑制剂。结构-活性关系很好地匹配了呋喃衍生物,以前已经进行了研究。在咪唑和恶唑化合物中,(2,5-二取代)苯基化合物均显示出比其他类似物更好的活性。特别是2-(2,5-二氯苯基)咪唑52和2-(2-甲氧基-5-氯苯基)咪唑54化合物在体外和体内均显示出强力的心脏保护功效以及高的NHE-1抑制活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号